Migraine is the third most common illness in the world. One in seven people are affected at some point in their lives. Those who suffer from chronic migraines – that is, having at least fifteen headache days per month, of which eight consist of migraines – often have to limit their lives and take medications with severe side effects. Normally, you cannot work during a migraine attack, which results in large costs to society in the form of both medical care and loss of production. Our Ozilia® Migraine method is expected to preventively decrease the number of headache days, which is what the current study intends to prove.
Dr. Emilia Tauriala is a specialist in neurology, Chief Medical Officer at Terveystalo – one of Finland’s largest private healthcare companies – and one of the principal investigators who led the work on Chordate Medical’s study PM-007 in Finland. In an interview with BioStock, she discusses the study work, the benefits of Ozilia, and the significant need for new treatments for chronic migraine.
”The headache days were significantly reduced when comparing the real internasal stimulation to sham stimulation. The side effect profile is very different. Ozilia mostly gives side effects during those 20 minutes when you receive the treatment, but the rest of the week you’re “free to go” so to speak. Currently, available treatments for migraine prevention include medication mostly. So, we have blood pressure medication, anti-depressants, and anti-epileptic drugs available for most patients. While they can be effective for some individuals, they’re not always successful in reducing migraine days or the severity of the attacks, and they may also have unwanted side effects. It is actually quite common that the side effects prevent use of those treatments”
On September 8, 2022, an abstract featuring subgroup results from Chordate Medical’s migraine study PM007 was presented at the Migraine Trust International Symposium 2022 in London. BioStock interviewed Dr. Jan Hoffmann, the author of the abstract, during the symposium.
”I think for patients, it does make a big difference. The reason is, we do have a lot of preventives but this is by far a new solution. Because first of all we usually have a response rate somewhere between 50 and 60 something percent. So a significant part of the patients do not respond. Then we have the second problem which is that they have a lot of side effects. If you use anti depressives, if you use anticonvulsants, you usually have weight gain, you have tiredness, concentration difficulties, you can get depressed with some of them. So these are side effects that can effect the quality of life for patients significantly. And the attractiveness of this treatment (Ozilia), is that it is essentially a local treatment in the nasal cavity that then has an effect on the migraine frequency, but you do not expect any systemic side effects.”
For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of Ozilia®, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.
